Langan Martin, J, McLean, G, Park, J, Martin, D, Connolly, M, Mercer, SW, et al. Impact of socioeconomic deprivation on rate and cause of death in severe mental illness. BMC Psychiatry
2014; 14: 2–10.
McLean, G, Langan Martin, J, Martin, D, Guthrie, B, Mercer, SW, Smith, DJ. Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: evidence from a national primary care database. Schizopr Res
2014; 159: 176–81.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Young, SL, Taylor, M, Lawrie, SM. First do no harm: a systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol
2015; 29: 353–62.
Oh, GH, Yu, JC, Choi, KS, Joo, EJ, Jeong, SH. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investig
2015; 12: 46–54.
Henderson, DC, Cagliero, E, Gray, C, Nasrallah, RA, Hayden, DL, Schoenfeld, DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry
2000; 157: 975–81.
Czobor, P, Volavka, J, Sheitma, B, Lindenmaye, J-P, Citrome, L, Mcevoy, J, et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol
2002; 22: 244–51.
Khanna, P, Suo, T, Komossa, K, Ma, H, Rummel-Kluge, C, El-Sayeh, H, et al. Aripiprazole versus other atypical antipsychotics. Cochrane Database Syst Rev
2014; 1: CD006569.
BNF Publications. British National Formulary 69
. Pharmaceutical Press, 2015.
Langan Martin, J, Lowrie, R, McConnachie, A, McLean, G, Mair, F, Mercer, SW, et al. Physical health indicators in major mental illness: evidence of reduced uptake from UK-wide QOF data. Br J Gen Pract
2014; 64: e649–656.
Manu, P, Khan, S, Radhakrishnan, R, Russ, MJ, Kane, JM, Correll, CU. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry
2014; 75: e573–7.
NHS Lanarkshire. Public Health 2013/14: The Annual Report of the Director of Public Health. Lanarkshire NHS Board, 2014.
Rouillon, F, Sorbara, F.
Schizophrenia and diabetes: epidemiological data. Eur Psychiatry
2005; 20: S345–8.
Foley, DL, MacKinnon, A, Watts, GF, Shaw, JE, Magliano, DJ, Castle, DJ, et al. Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. PLoS One
2013; 8: e82606.
De Hert, M, Vancampfort, D, Correll, CU, Mercken, V, Peuskens, J, Sweers, K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry
2011; 199: 99–105.
DeFronzo, RA, Ferrannini, E.
Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care
1991; 14: 173–94.
Bushe, CJ, Leonard, BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry
2007; 68: 1682–90.
Lobo, FS, Wagner, S, Gross, CR, Schommer, JC. Addressing the issue of channelling bias in observational studies with propensity scores analysis. Res Social Adm Pharm
2006; 2: 143–51.
Kinon, BJ, Basson, BR, Gilmore, JA, Tollefson, GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry
2001; 62: 92–100.
Shiers, DE, Rafi, I, Cooper, SJ, Holt, RIG. Positive Cardiometabolic Health Resource: An Intervention Framework for Patients with Psychosis and Schizophrenia
. Royal College of Psychiatrists, 2014.